Glucagon-like peptide-1 (GLP-1) receptor agonists are increasingly used in the treatment of medlinktype 2 diabetes/medlink and...

learn about suicide and self-harm risks among users of GLP-1 receptor agonists for type 2 diabetes, obesity, and mental health outcomes

learn about suicide and self-harm risks among users of GLP-1 receptor agonists for type 2 diabetes, obesity, and mental health outcomes

TUESDAY, Sept. 17, 2024 -- For patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and diabetes, glucagon-like peptide 1...

They were developed as diabetes drugs, then their potential for promoting significant weight loss became apparent. And now study after study seems to...

FRIDAY, Sept. 13, 2024 -- Initially approved to treat type 2 diabetes, Ozempic and Mounjaro also can help people with type 1 diabetes lose weight and...

FRIDAY, Sept. 13, 2024 -- Initially approved to treat type 2 diabetes, Ozempic and Mounjaro also can help people with type 1 diabetes lose weight and...

FRIDAY, Sept. 13, 2024 -- Ozempic and its weight-loss cousin, Wegovy, outperform another longstanding weight-loss drug that targets the same hormone...

MONDAY, Sept. 16, 2024 -- Fatty liver disease linked to diabetes and obesity can easily progress to liver cirrhosis, but new research suggests that...

As surprise pregnancies multiply, some scientists are investigating whether weight loss drugs can improve fertility in women with polycystic ovary...